LONDON Oct 13 Pfizer suffered a setback
in Britain on Thursday when the Court of Appeal in London ruled
against it in a patent case over the use of its $5
billion-a-year drug Lyrica for pain relief.
Pfizer said it would seek a further appeal.
Lyrica, known generically as pregabalin, was originally
developed for epilepsy. However, further research showed it
could also help patients suffering from neuropathic pain and
most prescriptions are now written for pain.
While the original patent on pregabalin has expired, Pfizer
was awarded a secondary patent covering pain, valid until July
2017, and the U.S. drugmaker had been fighting to protect this
lucrative section of the market.
(Reporting by Ben Hirschler; Editing by Tom Bergin)